Bicycle Therapeutics plc (FRA:50BA)

Market Cap	288.62M -28.7%
Revenue (ttm)	61.82M +105.8%
Net Income	-186.49M
EPS	-2.69
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	18
Open	3.980
Previous Close	4.120
Day's Range	3.980 - 4.040
52-Week Range	3.600 - 8.450
Beta	n/a
RSI	47.76
Earnings Date	May 1, 2026

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted imm...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 288
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 50BA

Financial Performance

In 2025, Bicycle Therapeutics's revenue was $72.59 million, an increase of 105.77% compared to the previous year's $35.28 million. Losses were -$218.96 million, 29.5% more than in 2024.

Financial numbers in USD